Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.48 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.48 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.48 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.46 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.45 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.44 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17616608 | 0.89 | MRGPRX4 (0.58) | L3MBTL1SMN1; SMN2MAPTHTTLMNA | |
| SCHEMBL8782224 | 0.88 | PTGER1 (0.47) | L3MBTL1SMN1; SMN2MAPTHTTLMNA | |
| SCHEMBL17616657 | 0.87 | MRGPRX4 (0.51) | L3MBTL1SMN1; SMN2MAPTHTTLMNA | |
| SCHEMBL17616619 | 0.85 | MAPT (0.48) | L3MBTL1SMN1; SMN2MAPTHTTLMNA | |
| SCHEMBL17616662 | 0.85 | MRGPRX4 (0.60) | L3MBTL1SMN1; SMN2MAPTHTTLMNA | |
| SCHEMBL8782368 | 0.84 | PTGER1 (0.45) | L3MBTL1SMN1; SMN2MAPTHTTLMNA | |
| SCHEMBL17616658 | 0.82 | FFAR1 (0.47) | L3MBTL1SMN1; SMN2MAPTHTTLMNA | |
| SCHEMBL18178489 | 0.78 | L3MBTL1 (0.48) | L3MBTL1SMN1; SMN2MAPTLMNAPTGER1 | |
| SCHEMBL18749825 | 0.78 | KDM4E (0.48) | L3MBTL1SMN1; SMN2MAPTHTTPTGER1 | |
| SCHEMBL17616638 | 0.78 | L3MBTL1 (0.50) | L3MBTL1SMN1; SMN2MAPTHTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9675072-B2 | Tetrazolinone compound and application of same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-06-13 | — | — | US | disclosed |
| US-9512090-B2 | Tetrazolinone compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-12-06 | — | — | US | disclosed |
| US-20160159755-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-06-09 | — | — | US | disclosed |
| EP-3006440-A1 | TETRAZOLINONE COMPOUND AND APPLICATION OF SAME | Sumitomo Chemical Company Limited (JP) | 2016-04-13 | — | — | EP | disclosed |
| US-20160081340-A1 | TETRAZOLINONE COMPOUND AND APPLICATION OF SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159755-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | CYP1A1, CASP1, TCOF1 | L3MBTL1 170/4885SMN1; SMN2 3877/4885MAPT 2985/4885 |
| US-20160081340-A1 | TETRAZOLINONE COMPOUND AND APPLICATION OF SAME | CYP2E1, MT-CO2, CASP3 | L3MBTL1 458/4885SMN1; SMN2 2650/4885MAPT 3398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.